CT26 murine colon carcinoma expressing the red fluorescent protein KillerRed as a highly immunogenic tumor model

Abstract. The development of tumor therapies based on the activation of antitumor immunity requires tumor models that are highly immunogenic. The immunologic response to fluorescent proteins, green fluorescent protein (GFP), or enhanced GFP (EGFP) was demonstrated in different cancer models. However, for live animal imaging, red and far-red fluorescent proteins are preferable, but their immunogenicity has not been studied. We assessed the immunogenicity of the red fluorescent protein, KillerRed (KR), in CT26 murine colon carcinoma. We showed a slower growth and a lower tumor incidence of KR-expressing tumors in comparison with nonexpressing ones. We found that KR-expressing lung metastases and rechallenged tumors were not formed in mice that had been surgically cured of KR-expressing primary tumors. The effect of low-dose cyclophosphamide (CY) treatment was also tested, as this is known to activate antitumor immune responses. The low-dose CY therapy of CT26-KR tumors resulted in inhibition of tumor growth and improved mouse survival. In summary, we have established a highly immunogenic tumor model that could be valuable for investigations of the mechanisms of antitumor immunity and the development of new therapeutic approaches.

[1]  Eli Gilboa,et al.  The determinants of tumour immunogenicity , 2012, Nature Reviews Cancer.

[2]  V. Cicinnati,et al.  Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope , 2000, Gene Therapy.

[3]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[4]  David Escors,et al.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. , 2014, New journal of science.

[5]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[6]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[7]  I. Zagon,et al.  Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin , 2011, Experimental biology and medicine.

[8]  W. Falk,et al.  GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice , 2004, Clinical & Experimental Metastasis.

[9]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[10]  Wanjun Chen,et al.  Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression , 2011, International journal of biological sciences.

[11]  M. Field,et al.  Diffusion pathways of oxygen species in the phototoxic fluorescent protein Killer Red , 2010, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[12]  G. Opelz,et al.  Immunosuppressive Effect of Tryptophan Metabolites in Composite Tissue Allotransplantation , 2007, Plastic and reconstructive surgery.

[13]  C. Sautès-Fridman,et al.  Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics , 2011, Clinical and experimental immunology.

[14]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[15]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[16]  Konstantin A Lukyanov,et al.  A genetically encoded photosensitizer , 2006, Nature Biotechnology.

[17]  Michael Dougan,et al.  Immune therapy for cancer. , 2009, Annual review of immunology.

[18]  K. Tanabe,et al.  Cancer immunoediting from immune surveillance to immune escape , 2007, Immunology.

[19]  Elena V. Zagaynova,et al.  Light-induced blockage of cell division with a chromatin-targeted phototoxic fluorescent protein. , 2011, The Biochemical journal.

[20]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[21]  Marina V Shirmanova,et al.  Phototoxic effects of fluorescent protein KillerRed on tumor cells in mice , 2013, Journal of biophotonics.

[22]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[23]  D. Kohn,et al.  Immune response to green fluorescent protein: implications for gene therapy , 1999, Gene Therapy.

[24]  C. Schmitt,et al.  Stromal Interferon-γ Signaling and Cross-Presentation Are Required to Eliminate Antigen-Loss Variants of B Cell Lymphomas in Mice , 2012, PloS one.

[25]  J. Lustgarten,et al.  Aged Mice Develop Protective Antitumor Immune Responses with Appropriate Costimulation1 , 2004, The Journal of Immunology.

[26]  P. Musiani,et al.  OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response1 , 2003, The Journal of Immunology.

[27]  Trans-illumination fluorescence imaging of deep-seated tumors in small animals , 2015 .

[28]  S. Lukyanov,et al.  Fluorescent proteins and their applications in imaging living cells and tissues. , 2010, Physiological reviews.

[29]  Michael R Hamblin,et al.  Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model , 2008, Proceedings of the National Academy of Sciences.

[30]  B. Nathwani,et al.  Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome‐related lymphoma: Effect on human immunodeficiency virus and serum interleukin‐6 levels over time , 1996, Cancer.

[31]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[32]  B. Vogelstein,et al.  Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. , 1988, Cancer research.

[33]  D. Skelton,et al.  The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice , 2001, Gene Therapy.

[34]  A. Wlodawer,et al.  Structural Basis for Phototoxicity of the Genetically Encoded Photosensitizer KillerRed* , 2009, The Journal of Biological Chemistry.

[35]  D. Getnet,et al.  Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. , 2009, Cancer research.

[36]  S. Swisher,et al.  Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy , 2007, Cancer biology & therapy.

[37]  P. Krammer,et al.  Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.

[38]  M. Overdijk.  Antibody therapy of cancer : Fc receptor-mediated mechanisms of action , 2013 .

[39]  J. Johnston,et al.  B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. , 1994, Cancer research.

[40]  Andreas S Bommarius,et al.  Reactive oxygen species in photochemistry of the red fluorescent protein "Killer Red". , 2011, Chemical communications.

[41]  Michael R Hamblin,et al.  A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy , 2006, British Journal of Cancer.